As the VMware vSphere 7 Support Deadline Nears, Spinnaker Announces Alternative Option to Keep VMware Customers Supported Indefinitely
22.9.2025 14:00:00 CEST | Business Wire | Press Release
Spinnaker Support (Spinnaker), the Oracle, SAP and VMware software support specialist trusted by over 1,000 global clients, including many of the world’s leading banks, telcos and utility companies, announces today that it will provide support for organizations running vSphere 7 indefinitely - meaning organizations running vSphere 7 for as long as they want past Broadcom’s End of General Support Deadline (EoGS) of October 2, 2025.
From October 2, 2025, Broadcom will no longer provide technical support, security patches, or updates for vSphere 7.x, and customers will need to upgrade to a newer version if they want to remain supported. If customers decide not to upgrade or simply don’t have the budget to do so, systems will become vulnerable.
“Broadcom is essentially telling customers “Upgrade now or you’ll be left behind”, and we believe that is wrong,” said Shane O'Rourke, Senior Director of VMware Global Support Services, Spinnaker Support. “This is why today we are announcing that VMware customers running vSphere 7 can continue to do so as long as they want and remain supported by our team of VMware experts. This once again demonstrates Broadcom’s attitude towards customers and ultimately forcing them to upgrade when they are happy with their current version.”
“Many of the customers I talk to are still running on version 7, often because it’s “just working” and nobody wants to fix what isn’t broken. But as support winds down, the risks for these customers only compound: no more CVEs, no more zero-day patches, and no guarantees if something fundamental fails. From my perspective, now is the time to step back and look at what’s actually right for your business, your use cases, and your environment, not just what the vendor lifecycle dictates,” added O’Rourke.
David McDougall, CRO, Spinnaker Support commented: “Since the Broadcom acquisition, ambiguity is the only thing we’ve been able to count on. Customers distrust the licensing changes, many outright reject the move to a subscription model, and most simply want to avoid getting caught in another round of sudden price hikes, changing terms, or forced upgrades driven by the vendor. VMware has unwittingly pushed many customers into running their environments unsupported. The decision to shed your support contract isn’t something anyone is doing without serious consideration, and many customers feel like they have no alternative in the face of the VMware changes. It’s critical that organizations know that there is an alternative support option available to them.”
For more information about Spinnaker Support’s VMware support offering, visit https://www.spinnakersupport.com/vmware/.
About Spinnaker Support
Spinnaker Support is entrusted by over 1,000 companies worldwide to solve their most pressing and essential enterprise software needs.
Spinnaker Support experts provide an extensive services portfolio of third-party support, managed services, consulting, and state-of-the-art security to optimize clients’ software ecosystems. They support Oracle, SAP, and VMware – freeing up valuable capital and resources so customers can maximize the security and performance of their enterprise software ecosystem with certainty. With Spinnaker, enterprises are empowered to make software decisions based on their business initiatives rather than their enterprise software provider’s roadmap.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250922678118/en/
Contacts
Media contact
Dan Walsh
dan@mustardpr.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press Release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press Release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press Release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom